Decline in Public Spending on Biopharmaceutics in Brazil

Biopharmaceuticals, mainly monoclonal antibodies, and fusion proteins are drugs that have gained notoriety in the treatment of various chronic inflammatory diseases high prices. The study aimed to verify which antibodies were most incorporated into Unified Health System (SUS), therapeutic indication benefited from them analyze public spending on these biopharmaceuticals January 2012 September 2019. This performed a qualitative quantitative analysis by SUS. data collected websites CONITEC Price Bank. results demonstrated subcutaneous adalimumab was frequently incorporated, requested rheumatoid arthritis. Public exceeded R$ 28 billion (more than US$ 140 billion). However, downward trend confirmed (-266.7%) period evaluated. Despite increase demand biologics general, Brazil worldwide, this research show there drop studied last seven years.